O6-Benzylguanine
Appearance
Names | |
---|---|
IUPAC name
6-(Benzyloxy)-7H-purin-2-amine
| |
Other names
6-(Benzyloxy)guanine; 6-O-Benzylguanine; O(6)-bGua; O6-BG
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.161.788 |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C12H11N5O | |
Molar mass | 241.254 g·mol−1 |
Density | 1.432 g/mL |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
O6-Benzylguanine (O6-BG) is a synthetic derivative of guanine. It is an antineoplastic agent. It exerts its effect by acting as an inhibitor of the enzyme O6-alkylguanine-DNA alkyltransferase which leads to interruption of DNA repair and increases the potency of other chemotherapeutic agents that damage DNA, such as temozolomide.[1][2]
O6-BG is also used as a biochemical tool in the study of DNA repair mechanisms.
References
- ^ Quinn, JA; Desjardins, A; Weingart, J; Brem, H; Dolan, ME; Delaney, SM; Vredenburgh, J; Rich, J; et al. (2005). "Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23 (28): 7178–87. doi:10.1200/JCO.2005.06.502. PMID 16192602.
{{cite journal}}
: CS1 maint: numeric names: authors list (link) - ^ Quinn, J. A.; Jiang, S. X.; Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Rich, J. N.; Gururangan, S.; Friedman, A. H.; et al. (2009). "Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults with Recurrent, Temozolomide-Resistant Malignant Glioma". Journal of Clinical Oncology. 27 (8): 1262–7. doi:10.1200/JCO.2008.18.8417. PMC 2667825. PMID 19204199.
External links
- Friedman, HS (2000). "Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?" (PDF). Clinical Cancer Research. 6 (8): 2967–8. PMID 10955771.